Overview

* Oscar Health ( OSCR ) Q3 revenue rises but misses analyst expectations

* Adjusted EBITDA for Q3 beats analyst estimates, despite net loss

* Company reaffirms full-year 2025 guidance and settles part of 2031 notes

Outlook

* Oscar Health ( OSCR ) reaffirms 2025 revenue guidance of $12.0 bln to $12.2 bln

* Company expects 2025 medical loss ratio between 86.0% and 87.0%

* Oscar Health ( OSCR ) projects 2025 SG&A expense ratio between 17.1% and 17.6%

Result Drivers

* HIGHER MEMBERSHIP - Revenue growth driven by increased membership, despite missing analyst expectations

* INCREASED MARKET MORBIDITY - Higher medical loss ratio due to increased average market morbidity, impacting financial results

* COST MANAGEMENT - SG&A expense ratio decreased due to greater fixed cost leverage and disciplined cost management

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $2.99 $3.08

Revenue bln bln (8

Analysts

)

Q3 Net -$137.45

Income mln

Q3 Beat -$101.45 -$102.94

Adjusted mln mln (5

EBITDA Analysts

)

Q3 $3.12

Operatin bln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and 5 "sell" or "strong sell"

* The average consensus recommendation for the life & health insurance peer group is "buy."

* Wall Street's median 12-month price target for Oscar Health Inc ( OSCR ) is $13.00, about 31% below its November 5 closing price of $17.03

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)